Mitomycin Medac

Mitomycin, the active ingredient in Mitomycin Medac, is an antineoplastic antibiotic presented as a sterile solution for intravenous and intravesical use. It is employed in the treatment of several solid tumours, including bladder cancer administered directly into the bladder, as well as gastric, pancreatic and certain lung cancers.

GNH USA supplies Mitomycin Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mitomycin Medac is used in oncology to target DNA synthesis in malignant cells across several tumour types. - Bladder cancer (intravesical): provides local cytotoxic activity to reduce tumour recurrence after transurethral resection. - Gastric carcinoma: used as part of combination regimens to improve response rates in advanced disease. - Pancreatic carcinoma: contributes to tumour shrinkage when combined with other chemotherapeutics. - Non‑small cell lung cancer: incorporated into multi‑drug protocols for selected patients with advanced disease.

Mitomycin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Myelosuppression: reduced white blood cells, platelets, and red cells. - Hematuria: blood in urine, especially after intravesical administration. - Fatigue: generalized tiredness during treatment cycles.

Serious or Rare Side Effects: - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Severe renal impairment: acute kidney injury, particularly with intravesical use. - Life‑threatening infections: due to profound neutropenia. - Allergic reactions: rash, urticaria, or anaphylaxis. - Secondary malignancies: rare risk of therapy‑related cancers.

Mitomycin requires careful monitoring and specific handling to minimise risks. - Renal function: assess baseline creatinine and adjust use in renal impairment. - Hepatic function: monitor liver enzymes before and during therapy. - Hematologic monitoring: perform regular complete blood counts to detect myelosuppression. - Pregnancy and lactation: avoid use; discuss risks with a specialist if pregnancy is possible. - Concomitant nephrotoxic agents: avoid or use with caution to reduce renal toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mitomycin may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - High‑dose cyclophosphamide: increased risk of severe bone‑marrow suppression. - Nephrotoxic antibiotics (e.g., aminoglycosides): heightened renal toxicity. - Strong CYP450 inducers: may reduce plasma concentrations of Mitomycin.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., fluconazole): potential additive myelosuppression. - NSAIDs: may exacerbate renal impairment. - Radiation therapy: combined use can increase tissue toxicity.